About Armata Pharmaceuticals
Armata Pharmaceuticals is a company based in Los Angeles (United States) founded in 1989. The company has 60 employees as of December 31, 2024. Armata Pharmaceuticals offers products and services including Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03. Armata Pharmaceuticals operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
- Headquarter Los Angeles, United States
- Employees 60 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Armata Pharmaceuticals, Inc.
-
Annual Revenue
$5.17 M (USD)14.24as on Dec 31, 2024
-
Net Profit
-$18.92 M (USD)72.6as on Dec 31, 2024
-
EBITDA
-$41.11 M (USD)-2.99as on Dec 31, 2024
-
Latest Funding Round
$26.9 M (USD), Post-IPO
Apr 01, 2022
-
Investors
Cystic Fibrosis Foundation
& 2 more
-
Employee Count
60
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Armata Pharmaceuticals
Armata Pharmaceuticals is a publicly listed company on the AMEX with ticker symbol ARMP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Armata Pharmaceuticals
Armata Pharmaceuticals offers a comprehensive portfolio of products and services, including Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03.
Phage-based treatments targeting bacterial infections.
Platform for developing advanced phage therapeutics.
Clinical programs for specific phage therapeutics.
People of Armata Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Armata Pharmaceuticals
Investors in Armata Pharmaceuticals
Armata Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Cystic Fibrosis Foundation, Innoviva and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Respiratory prescription drugs are developed and in-licensed for COPD treatment.
|
Locked | Locked | Locked | |
|
Research funding and support for cystic fibrosis patients are provided.
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Armata Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Armata Pharmaceuticals
Investment portfolio details for Armata Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Armata Pharmaceuticals
Detailed financials for Armata Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Armata Pharmaceuticals Comparisons
Peer comparison for Armata Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Armata Pharmaceuticals
Armata Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and BiomX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Microbiome therapeutics are developed for dysbiosis-linked diseases.
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Armata Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Armata Pharmaceuticals
Complete news archive for Armata Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Armata Pharmaceuticals
Armata Pharmaceuticals was founded in 1989 and raised its 1st funding round 19 years after it was founded.
Armata Pharmaceuticals is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Deborah L Birx is the current CEO of Armata Pharmaceuticals.
As of Dec 31, 2024, the latest employee count at Armata Pharmaceuticals is 60.
Annual revenue of Armata Pharmaceuticals is $5.17M as on Dec 31, 2024.
Armata Pharmaceuticals was founded in 1989 in Los Angeles, United States, within the biotechnology sector. Phage therapeutics are developed by the company to address key antibiotic-resistant bacteria. The lead candidate, AP-SA01, is targeted at Staphylococcus aureus, including multidrug-resistant strains. A pipeline of proprietary synthetic phage candidates is also advanced, such as one for Pseudomonas aeruginosa. Operations focus on therapeutic development for infectious diseases.
Armata Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Armata Pharmaceuticals offers Bacteriophages, Synthetic Phage Platform, and AP-PA02 & AP-PA03.
Yes, Armata Pharmaceuticals is publicly traded on AMEX under the ticker symbol ARMP.
Armata Pharmaceuticals has 3 investors. Key investors include Cystic Fibrosis Foundation, Innoviva, and Military Health.
The ticker symbol of Armata Pharmaceuticals is ARMP on AMEX.